Ashfield reports back from the Orphan Drugs for Rare Diseases Summit

The event was well attended by healthcare experts and industry leaders, all keen to share learnings and experiences in the field of rare diseases. Through a series of presentations, the event explored the challenges of rare diseases from different perspectives including: High science and clinical development Commericalisation Patient support and communication Regulatory Some of the presentations focused on specific rare diseases whilst others explored broader themes. Highlights included: ‘Developing therapies for monogenic neurodegenerative disorders’ presented by Dr. Rajeev Sivasankaran Head – Rare Diseases, Neuroscience Division, Novartis Institution for BioMedical Research ‘From rare to common: targeting Gaucher defects for the treatment of Parkinson’s Disease’ presented by Dr. Pablo Sardi, Neuroscience Therapeutic Area, Sanofi ‘Precision medicine in chronic kidney diseases: zooming in and out rare diseases’ presented by Dr. Maria Chiara Magnone, Sr Director, Head of Translational Sciences CVMD iMed, AstraZeneca As sponsors of the conference, Ashfield was delighted to attend, meet with our pharma clients and deliver a presentation. Matt Brierley, VP Medical and Scientific Services, and Nagore Fernandez, Head of Patient Services for EUCAN, presented ‘From infancy to adulthood: a new generation of challenges for rare disease communities’ covering: Enabling timely, successful patient diagnosis Addressing evolving...
Source: Ashfield Healthcare News - Category: Pharmaceuticals Authors: Tags: Ashfield Source Type: news